3-羟基喹洛啉-3-甲腈 | 6238-30-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 奎宁环
• 中文名称: 3-羟基喹洛啉-3-甲腈
• 英文名称: 3-hydroxy-1-azabicyclo[2.2.2]octane-3-carbonitrile
• 英文别名: 3-cyano-3-hydroxyquinuclidine；3-hydroxy-3-cyanoquinuclidine；3-hydroxyquinuclidine-3-carbonitrile；3-cyano-3-hydroxy-1-azabicyclo[2.2.2]octane
• CAS: 6238-30-8
• 化学式: C₈H₁₂N₂O
• 分子量: 152.196
• InChiKey: BEDKJKABPPDZNB-UHFFFAOYSA-N

物化性质

• 熔点：
  156 °C

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  47.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xn
• 危险类别码：
  R20/21/22
• 海关编码：
  2933990090
• 安全说明：
  S36/37
• 储存条件：
  室温

SDS

Name:	3-Hydroxyquinuclidine-3-carbonitrile 97% Material Safety Data Sheet
Synonym:
CAS:	6238-30-8

Section 1 - Chemical Product MSDS Name:3-Hydroxyquinuclidine-3-carbonitrile 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
6238-30-8	3-Hydroxyquinuclidine-3-carbonitrile	97%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. May cause respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 6238-30-8: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 161 - 164 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H12N2O
Molecular Weight: 152

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Reducing agents, strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen cyanide, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 6238-30-8 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Hydroxyquinuclidine-3-carbonitrile - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: NITRILES, SOLID, TOXIC, N.O.S.*
Hazard Class: 6.1
UN Number: 3276
Packing Group: III
IMO
Shipping Name: NITRILES, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 3276
Packing Group: III
RID/ADR
Shipping Name: NITRILES, TOXIC, N.O.S.
Hazard Class: 6.1
UN Number: 3276
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 36/37 Wear suitable protective clothing and
gloves.
WGK (Water Danger/Protection)
CAS# 6238-30-8: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 6238-30-8 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 6238-30-8 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-羟基喹洛啉-3-甲腈 在 硼烷 作用下， 以 四氢呋喃 为溶剂， 反应 12.0h， 以80%的产率得到3-Aminomethyl-3-hydroxyquinuclidine-borane
  参考文献：
  名称：

  Swain, Christopher J.; Kneen, Clare; Herbert, Richard, Journal of the Chemical Society. Perkin transactions I, 1990, # 11, p. 3183 - 3186

  摘要：

  DOI：
• 作为产物：
  描述：

  3-奎宁环酮盐酸盐 以 水 为溶剂， 以97%的产率得到3-羟基喹洛啉-3-甲腈
  参考文献：
  名称：

  Spirocyclic compounds incorporating five-membered rings with two

  摘要：

  本发明提供了公式I的化合物或其盐或前药：其中虚线表示两种可能位置中的一个可选化学键；A代表公式II的一个基团：其中R.sup.1代表氢、羟基、C.sub.1-6烷基、C.sub.2-6烯基、C.sub.2-6炔基、C.sub.1-6烷氧基、苄氧基、羟基(C.sub.1-6)烷基、卤素、氨基、氰基、硝基、-CONR.sup.6 R.sup.7或-SO.sub.2 NR.sup.6 R.sup.7，其中R.sup.6和R.sup.7独立地代表氢、卤素、C.sub.1-6烷基、C.sub.2-6烯基或C.sub.2-6炔基；R.sup.2代表氢、卤素、C.sub.1-6烷基、C.sub.1-6烷氧基或C.sub.1-6烷基羰基；V代表氮、-CH或-C-；W代表氧、硫或-NR.sup.8，其中R.sup.8代表氢、C.sub.1-6烷基、C.sub.2-6烯基或C.sub.2-6炔基；X、Y和Z中的两个相同或不同，每个代表氧、硫或氮；剩余的X、Y或Z是碳，或Y是羰基(C=O)；Q是氮杂环或氮杂双环环系统的残基；这些化合物在治疗精神分裂症（如精神分裂症和狂躁症）；焦虑症；酒精或药物戒断或依赖；疼痛；胃排空延迟；胃功能障碍（如消化不良、消化性溃疡、反流性食道炎和胀气）；偏头痛、恶心和呕吐；运动障碍；以及老年性痴呆症和老年性痴呆症方面具有用处。

  公开号：

  US04940703A1

文献信息

• Synthesis of 2′-Arylazabicyclo-3-spiro-4′(5′)-imidazolines
  作者：Brendan Whelan、Isabel Iriepa、Enrique Galvez

  DOI：10.1055/s-1994-25584

  日期：——

  A method is described for the synthesis of a series of 2′-aryl-3-azabicyclospiro-4′ (5′)-imidazolines via the reaction of azabicyclic 1,2-diamines with aryl imidate salts. Competing reactions in the synthesis of the diamines such as the reduction of amino nitriles with LiAlH4 lead to some anomalous products. In the Pinner synthesis, unstable pyridine-type imidates were stabilized as their N-oxide derivatives.

  本文描述了一种通过氮杂双环1,2-二胺与芳基亚氨盐反应合成一系列2′-芳基-3-氮杂双环螺-4′(5′)-咪唑啉的方法。在二胺的合成过程中，如氨基腈与LiAlH4的还原反应等竞争性反应导致一些异常产物的生成。在Pinner合成法中，不稳定的吡啶型亚氨盐被其N-氧化衍生物所稳定化。
• [EN] QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS<br/>[FR] COMPOSÉ DE QUINUCLIDINE COMME LIGANDS DU RÉCEPTEUR NICOTINIQUE ALPHA-7 DE L'ACÉTYLCHOLINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2011053292A1

  公开（公告）日：2011-05-05

  The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic 7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

  该披露提供了公式I的化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物是烟碱7受体的配体，可能对治疗中枢神经系统的各种紊乱，特别是情感和神经退行性疾病有用。
• QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS
  申请人：Cook, II James H.

  公开号：US20090270405A1

  公开（公告）日：2009-10-29

  The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.

  该披露提供了公式I的化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物是烟碱性α7受体的配体，可能对治疗中枢神经系统的各种疾病，特别是情感和神经退行性疾病，有用。
• Imidazole derivatives and salts thereof and pharmaceutical formulations
  申请人：Burroughs Wellcome Co.

  公开号：US04328234A1

  公开（公告）日：1982-05-04

  Imidazoles of formula (I) ##STR1## wherein A is a chemical bond or a straight or branched, saturated or unsaturated, aliphatic residue having from 1 to 6 carbon atoms wherein 1, 2 or 3 of such carbon atoms may be replaced by a corresponding number of heteroatoms selected from oxygen, sulphur and nitrogen providing (in the case of 2 or 3 heteroatoms) that any such heteroatom is not located adjacent to a further such heteroatoms or heteroatoms R is a fused, saturated or unsaturated, non-aromatic carbocyclic, polycyclic ring system; a saturated or unsaturated, carbocyclic spirocyclic ring system, optionally containing one or more ring heteroatoms selected from oxygen, sulphur and nitrogen; or a saturated or unsaturated, carbocyclic bridged-polycyclic ring system, optionally containing one or more ring heteroatoms selected from oxygen, sulphur and nitrogen and having one or more bridges; or AR together represent a straight or branched, saturated or unsaturated, aliphatic residue having 3 to 6 carbon atoms, wherein 1, 2 or 3 of such carbon atoms may be replaced by a corresponding number of heteroatoms selected from oxygen, sulphur and nitrogen providing (in the case of 2 or 3 heteroatoms) that any such heteroatom is not located adjacent to a further such heteroatom or heteroatoms; which aliphatic residue is substituted by at least two groups, which may be the same or different, selected from the groups specified for R above. and acid addition salts and pharmaceutically acceptable bioprecursors thereof. Methods of preparing the imidazoles are disclosed. The imidazoles and their acid addition salts and bioprecursors are useful in the treatment or prophylaxis of thrombo-embolic conditions.

  Imidazoles的化学式（I）##STR1##其中A是化学键或直链或支链、饱和或不饱和的、具有1至6个碳原子的脂肪残基，其中这些碳原子中的1、2或3个可以被氧、硫和氮等异原子取代，提供（在2或3个异原子的情况下）任何这样的异原子不位于另一个这样的异原子或异原子旁边R是融合的、饱和的或不饱和的、非芳香性碳环多环环系统；一个饱和或不饱和的、碳环螺环系统，可选地含有一个或多个氧、硫和氮等环异原子；或者是一个饱和或不饱和的、碳环桥联多环环系统，可选地含有一个或多个氧、硫和氮等环异原子并具有一个或多个桥梁；或者AR一起表示一个直链或支链、饱和或不饱和、具有3至6个碳原子的脂肪残基，其中这些碳原子中的1、2或3个可以被氧、硫和氮等异原子取代，提供（在2或3个异原子的情况下）任何这样的异原子不位于另一个这样的异原子或异原子旁边；这种脂肪残基被至少两个可能相同或不同的从上述R中指定的基团取代。其酸盐和药学上可接受的生物前体。揭示了制备咪唑的方法。咪唑及其酸盐和生物前体在治疗或预防血栓栓塞症方面是有用的。
• Novel spiro-quinuclidinyl derivatives for the treatment of central nervous system disorders
  申请人：Huang Yifang

  公开号：US20070014751A1

  公开（公告）日：2007-01-18

  The present invention is directed to novel spiro-quinuclidinyl derivatives, pharmaceutical compositions containing them and their use in the treatment of central nervous system disorders.

  本发明涉及新型螺环喹啉基衍生物，包含它们的药物组合物以及它们在治疗中枢神经系统疾病中的用途。